Arash Moghaddam

Dr. Arash Moghaddam


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Injury
Verified
Journal Article
Closed access
AMArash Moghaddam
Arash Moghaddam
SZSeverin Zietzschmann
Severin Zietzschmann
TBThomas Bruckner
Thomas Bruckner
GSGerhard Schmidmaier
Gerhard Schmidmaier

Verified
Journal Article
Open access
PDF file
AMArash Moghaddam
Arash Moghaddam
CCChristopher Child
Christopher Child
TBThomas Bruckner
Thomas Bruckner
HGHans Jürgen Gerner
Hans Jürgen Gerner
VDVolker Daniel
Volker Daniel
BBBahram Biglari
Bahram Biglari
Pro- and anti-inflammatory cytokines might have a large impact on the secondary phase and on the neurological outcome of patients with acute spinal cord injury (SCI). We measured the serum levels of different cytokines (Interferon-γ, Tumor Necrosis Factor-α, Interleukin-1β, IL-6, IL-8, IL-10, and Vascular Endothelial Growth Factor) over a 12-week period in 40 acute traumatic SCI patients: at admission on average one hour after initial trauma; at four, nine, 12, and 24 h; Three, and seven days after admission; and two, four, eight, and twelve weeks after admission. This was done using a Luminex Performance Human High Sensitivity Cytokine Panel. SCI was classified using the American Spinal Injury Association (ASIA) Impairment Scale (AIS) at time of admission and after 12 weeks. TNFα, IL-1β, IL-6, IL-8, and IL-10 concentrations were significantly higher in patients without neurological remission and in patients with an initial AIS A (p < 0.05). This study shows significant differences in cytokine concentrations shown in traumatic SCI patients with different neurological impairments and within a 12-week period. IL-8 and IL-10 are potential peripheral markers for neurological remission and rehabilitation after traumatic SCI. Furthermore our cytokine expression pattern of the acute, subacute, and intermediate phase of SCI establishes a possible basis for future studies to develop standardized monitoring, prognostic, and tracking techniques.

7 June 2016 in Journal of Materials Science: Materials in Medicine
Verified
Journal Article
Closed access
PDF file
FWFabian Westhauser
Fabian Westhauser
CWChristian Weis
Christian Weis
MPMatthäus Prokscha
Matthäus Prokscha
LBLeonie A. Bittrich
Leonie A. Bittrich
WLWei Li
Wei Li
AMArash Moghaddam
Arash Moghaddam

6 April 2012 in Der Unfallchirurg
Verified
Journal Article
Closed access
PDF file
AMArash Moghaddam
Arash Moghaddam
GZG. Zimmermann
G. Zimmermann
ABA. Büchler
A. Büchler
CEC. Elleser
C. Elleser
BBB. Biglari
B. Biglari
CWC.G. Wölfl
C.G. Wölfl

1 March 2017 in Journal of Orthopaedics
Verified
Journal Article
Closed access
AMArash Moghaddam
Arash Moghaddam
BTBenjamin Thaler
Benjamin Thaler
TBThomas Bruckner
Thomas Bruckner
MTMichael Tanner
Michael Tanner
GSGerhard Schmidmaier
Gerhard Schmidmaier

22 July 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMArash Moghaddam
Arash Moghaddam
ASAndré Sperl
André Sperl
RHRaban Heller
Raban Heller
KKKevin Kunzmann
Kevin Kunzmann
VGViola Graeser
Viola Graeser
BBBahram Biglari
Bahram Biglari
After traumatic spinal cord injury, an acute phase triggered by trauma is followed by a subacute phase involving inflammatory processes. We previously demonstrated that peripheral serum cytokine expression changes depend on neurological outcome after spinal cord injury. In a subsequent intermediate phase, repair and remodeling takes place under the mediation of growth factors such as Insulin-like Growth Factor 1 (IGF-1). IGF-1 is a promising growth factor which is thought to act as a neuroprotective agent. Since previous findings were taken from animal studies, our aim was to investigate this hypothesis in humans based on peripheral blood serum. Forty-five patients after traumatic spinal cord injury were investigated over a period of three months after trauma. Blood samples were taken according to a fixed schema and IGF-1 levels were determined. Clinical data including AIS scores at admission to the hospital and at discharge were collected and compared with IGF-1 levels. In our study, we could observe distinct patterns in the expression of IGF-1 in peripheral blood serum after traumatic spinal cord injury regardless of the degree of plegia. All patients showed a marked increase of levels seven days after injury. IGF-1 serum levels were significantly different from initial measurements at four and nine hours and seven and 14 days after injury, as well as one, two and three months after injury. We did not detect a significant correlation between fracture and the IGF-1 serum level nor between the quantity of operations performed after trauma and the IGF-1 serum level. Patients with clinically documented neurological remission showed consistently higher IGF-1 levels than patients without neurological remission. This data could be the base for the establishment of animal models for further and much needed research in the field of spinal cord injury.